enVVeno Medical Corporation reported that as of December 31, 2025, it held a cash and investments balance of approximately $28 million, highlighting its available liquidity at year end. The company also announced that it has regained compliance with the minimum bid price requirement and all other criteria for continued listing on The NASDAQ Stock Market, removing an immediate risk to its exchange listing. The announcement was made through a press release furnished as an exhibit to this report.
enVVeno Medical Corporation implemented a one-for-thirty-five reverse stock split of its common stock, effective January 20, 2026. Every 35 previously issued and outstanding shares were automatically combined into one share, with no change to the par value.
No fractional shares were issued; any fractional positions were rounded up to the nearest whole share. The number of common shares outstanding decreased from 22,946,223 to 655,606, while authorized common shares remain at 250,000,000.
The company proportionally adjusted outstanding stock options and warrants so that share amounts decreased by a factor of 35 and exercise prices increased by a factor of 35, preserving their overall economic value. The stock now trades on a reverse split-adjusted basis on Nasdaq under the symbol NVNO.
enVVeno Medical Corp’s chief executive officer and director, Robert A. Berman, reported insider transactions involving both common stock and equity awards. The Form 4 discloses a disposition of 22,236 shares of common stock, and a related filing shows changes in his derivative holdings.
In addition, 200,000 restricted stock units that were granted to him on November 30, 2021 under the company’s Amended and Restated 2016 Omnibus Incentive Plan were voluntarily surrendered and cancelled on December 16, 2025. These units were subject to vesting based on specified performance milestones, which were not achieved, so the unvested awards were given up and no longer provide rights to common shares.
enVVeno Medical Corp executive Hamed Alavi, the company’s Chief Technology Officer, reported a change in his equity holdings. A Form 4 filing shows that 50,000 restricted stock units were surrendered and cancelled at a price of $0. These units were originally issued on November 30, 2021 under the Amended and Restated 2016 Omnibus Incentive Plan and were subject to performance-based vesting conditions.
The filing explains that the specified performance milestones were not achieved, and therefore the unvested restricted stock units were voluntarily cancelled. Following this transaction, the number of derivative securities of this type beneficially owned by Alavi is reported as 0.
enVVeno Medical Corp executive reports cancellation of equity award. SVP & Chief Medical Officer Dr. Marc Glickman filed a beneficial ownership report showing that 100,000 restricted stock units were surrendered and cancelled after specified performance milestones tied to the award were not achieved. The units were originally granted on November 30, 2021 under the company’s Amended and Restated 2016 Omnibus Incentive Plan and a Restricted Stock Unit Agreement, and had been scheduled to expire on November 30, 2031. Following this transaction dated December 16, 2025, Dr. Glickman reports direct ownership of 1,600 shares of common stock and no remaining derivative securities from this RSU grant.
enVVeno Medical Corp reported that director Francis Duhay received an award of 135,883 stock options on December 11, 2025. The options allow him to buy the company's common stock at an exercise price of $0.325 per share and expire on December 11, 2035.
The award was granted under the company's Amended and Restated 2016 Omnibus Incentive Plan and will vest in equal quarterly installments on the last day of each fiscal quarter during 2026. Following this grant, he beneficially owns 135,883 derivative securities directly.
enVVeno Medical Corp reported a new stock option grant to a director. On December 11, 2025, the director received 135,883 stock options with an exercise price of $0.325 per share, expiring on December 11, 2035.
The options were issued under the Amended and Restated 2016 Omnibus Incentive Plan and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.
enVVeno Medical Corp director Matthew M. Jenusaitis reported receiving a grant of stock options in an SEC Form 4. On December 11, 2025, he was issued 135,883 stock options with an exercise price of $0.325 per share under the company’s Amended and Restated 2016 Omnibus Incentive Plan, as amended. These options relate to 135,883 shares of common stock and expire on December 11, 2035.
The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year. Following this grant, Jenusaitis beneficially owns 135,883 derivative securities, held directly.
enVVeno Medical Corp director Sanjay Shrivastava reported receiving stock options covering 135,883 shares of common stock. The options were granted on 12/11/2025 with an exercise price of $0.325 per share, expire on 12/11/2035, and were issued under the company’s Amended and Restated 2016 Omnibus Incentive Plan. The options were awarded at no cost and are held directly.
The award is subject to time-based vesting, with the 135,883 options scheduled to vest in equal quarterly installments on the last day of each fiscal quarter during the 2026 calendar year.
enVVeno Medical Corp director Francis Duhay reported selling 4,900 shares of common stock on December 11, 2025 at a weighted-average price of $0.3556 per share. The sale was executed in multiple trades during the day at prices ranging from $0.3554 to $0.3573. After this transaction, the director beneficially owns 92,544 shares of enVVeno Medical common stock. The filing states that the trade was completed under a Rule 10b5-1 trading plan that the reporting person adopted in June 2025, which is a pre-arranged plan for trading company stock.